Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$113.70 USD
-0.45 (-0.39%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $113.66 -0.04 (-0.04%) 6:48 PM ET
4-Sell of 5 4
C Value D Growth A Momentum C VGM
Brokerage Reports
Abbott Laboratories [ABT]
Reports for Purchase
Showing records 481 - 500 ( 542 total )
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Raising our CY11 & CY12 estimates in light of upward revision to management?s guidance
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Dropping Coverage Due to Analyst Departure
Provider: WEDBUSH SECURITIES INC.
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Pharmaceuticals and Positive Currency Support Second Quarter Sales Growth
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Another Black Eye For An ABT Cholesterol Drug -- We See Modest Financial Risk, But Worries Are Likely To Hurt The Stock For The Time-Being
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
FDA Panel Recommends Tighter TriLipix Label- Vote Is as We Expected.
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Emerging markets strategy to be an important growth driver in near to medium term....Several late-stage projects in growing Pharma pipeline to boost longer term growth
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Emerging markets strategy to be an important growth driver in near to medium term....Several late-stage projects in growing Pharma pipeline to boost longer term growth
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
The Big Disconnect: Solid Results Gave No Boost to the Stock
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Emerging markets strategy to be an important growth driver in near to medium term......
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
The Chinese Pharmaceutical Industry: Fortnightly Update
Provider: RODMAN & RENSHAW, CO.
Analyst: PIROS E
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Emerging markets strategy to become a more important growth driver in near to medium term
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
4Q Sales Boosted by 23% Pharmaceuticals Growth. EPS Grew at a Double-Digit Rate.
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S